ADVA
21.1.2020 09:02:12 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that it has successfully demonstrated Europe’s first 5G rail deployment in an operational environment. Using a combined optical and microwave transport solution, the demo succeeded in delivering multi-Gbit/s connectivity to fast-moving trains. Until now, supporting the handovers required for consistent broadband connectivity on trains traveling at speed was a major challenge. Built on ADVA’s G.metro passive optical technology and FSP 150 edge aggregation solution , the joint trial featured an integrated architecture for all train communication applications. Millimeter wave (mmWave) access points (APs) were used to maintain track-to-train connectivity as well as programmable mobility functions for seamless onboard services. Part of the EU’s Horizon 2020 5G-PICTURE project, the demo was conducted by ADVA, Blu Wireless Technology, CNIT, COMSA Industrial and the local railway operator and infrastructure manager, Ferrocarrils de la Generalitat de Catalunya (FGC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200121005201/en/
“With this demo, we’ve presented the blueprints for the future of rail telecommunication networks. We’ve shown how a combined optical and microwave 5G architecture can carry both critical and non-critical communications, dramatically simplifying deployments and delivering significant cost reduction,” said Jim Zou, senior engineer, advanced technology, ADVA. “Unlike traditional railway telecommunication networks that rely on separate infrastructures, what we’ve proposed with this demo is a unified, automated network able to support every application and prevent service interruptions. It delivers high-bandwidth internet access to passengers on the move, while also providing train operators with driver-to-control connectivity, access to surveillance cameras and mission-critical onboard applications. Now a single 5G network can provide all telco services for train companies, freight operators and passengers.”
Deployed across three stations of the FGC network in Barcelona, the 5G-PICTURE railway testbed interconnected a variety of end-user devices and compute resources using the most advanced optical and wireless network technologies. For the first time in Europe in a live operational scenario, the demo proved that a single integrated infrastructure can deliver safe, secure and reliable connectivity for all three categories of train line services: critical, performance and business. Along the track, it leveraged mmWave links that intelligently steered beams to the train’s rooftop antennae for optimal backhaul and access connectivity. These were connected to passive WDM add/drop nodes built with ADVA’s low-latency G.metro system and each mmWave AP was capable of dedicated 10Gbit/s connectivity. All the traffic from the trackside was further aggregated to the railway operator’s core network based on ADVA’s 100Gbit/s Ethernet aggregation technology.
“At FGC, we understand the value of leveraging emerging technology to achieve maximum efficiency and provide our passengers with the best available services. That’s why we’re so excited by the possibilities that this demo presents. It showed how we can harness an intelligent, open and scalable 5G network for everything from surveillance to passenger communications to mission-critical operational data transport,” commented Carles Terés Casals, director, R&D, FGC. “Train passengers are heavy users of mobile data. Whether it’s video streaming, replying to emails and social media or planning the next stage of their journey, they expect always-on access to advanced services. Providing ultra-reliable high-speed mobility on a virtual infrastructure shared with all other applications offers a way to meet that demand while removing complexity and saving significant cost.”
“This project is about completely transforming on-train connectivity for the digitalization strategy of the railway sector. It’s about providing massive high-quality wireless capacity to trains to enable cloud-based applications that improve performance and security in the railway sector. It’s also about being able to support new business and passenger applications,” said Manuel Alfageme, head of smart systems innovation, COMSA Industrial. “At COMSA, we have a formidable record of leading the way with rail innovation. By jointly demonstrating the technical and commercial viability of this technology in a live operational environment, we’re showing train operators and railway infrastructure managers that open, scalable and agile 5G networks are now possible in the railway vertical. The time has come for a new generation of integrated railway infrastructure.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200121005201/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
